Shorter chemo tested to fight cancer while protecting weakened immune systems
NCT ID NCT00006436
Summary
This study tested whether a shorter course of a specific chemotherapy combination (EPOCH-R) could effectively control a type of lymphoma in people with HIV. The goal was to see if stopping treatment soon after the cancer went into remission could still keep it away for at least a year, while potentially causing less damage to the immune system and lowering the risk of future infections. The trial enrolled 68 adults with HIV and a specific type of untreated lymphoma.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA, LARGE B-CELL, DIFFUSE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.